ReviewCurrent topics in medicinal chemistry2026
Potential Indicators for the Development of Hepatocellular Carcinoma: A Diagnostic Strategy.
Review in Current topics in medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MRI-Based Deep Learning and Radiomics Nomogram for Predicting Hepatocellular Carcinoma Recurrence Within Six Months After Thermal Ablation.Journal of hepatocellular carcinoma · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC), a primary malignancy of the liver, ranks among the top five most common cancers globally and is associated with high mortality due to its poor prognosis, late-stage detection, and limited therapeutic success. Early diagnosis is essential to improve treatment outcomes and survival rates. Biomarkers have emerged as vital tools for the early detection, prognosis, and therapeutic monitoring of HCC, with many detectable in serum or urine at quantifiable levels. These biomarkers may be overexpressed, downregulated, or involved in regulatory pathways affecting other proteins and molecules, thereby serving as potential indicators of tumor development. This review aims to provide an updated overview of promising HCC biomarkers, highlighting their diagnostic value and clinical utility. A structured literature search was conducted using PubMed, Scopus, and Web of Science databases for studies published. Eligible studies were selected based on predefined inclusion criteria, evaluated for quality, and thematically categorized according to the type and function of biomarkers. The review emphasizes the translational potential of these indicators in developing more effective diagnostic strategies for HCC.
Indexed as
Identifiers
40676790What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.